136
http://www.DGS-PraxisLeitlinien.deNr.
Nachweis
154
KAMPEN W.-U, FISCHER M. Einsatz offener Radionuklide in der Schmerztherapie. Der
Schmerz 2008. Springer Verlag; 22 (6): 699-706.
155
Keskinbora K, Pekel AF, Aydinli I. Gabapentin and an opioid combination versus opioid
alone for the management of neuropathic cancer pain: a randomized open trial. J Pain
Symptom Manage 2007; 34(2): 183-189.
156
Kim DY, Song HS, Ahn JS, Ryoo BY, Shin DB, Yim CY, Kim SY. The dosing frequency of susta-
ined-release opioids and the prevalence of end-of-dose failure in cancer pain control: a
Korean multicenter study. Support Care Cancer 2010; 19(2): 297-301.
157
Klepstad P, Fladvad T, Skorpen F, Bjordal K, Caraceni A, Dale O, Davies A, Kloke M,
Lundström S, Maltoni M, Radbruch L, Sabatowski R, Sigurdardottir V, Strasser F, Fayers
PM, Kaasa S. Influence from genetic variability on opioid use for cancer pain: a European
genetic association study of 2294 cancer pain patients. Pain 2011; 152(5): 1139-1145.
158
Knudsen AK, Brunelli C, Kaasa S, Apolone G, Corli O, Montanari M, Fainsinger R, Aass
N, Fayers P, Caraceni A, Klepstad P; European Palliative Care Research Collaborative;
European Pharmacogenetic Study. Which variables are associated with pain intensity and
treatment response in advanced cancer patients? Implications for a future classification
system for cancer pain. Eur J Pain 2011; 15(3): 320-327.
159
Kollender Y, Bickels J, Stocki D, Maruoani N, Chazan S, Nirkin A, Meller I, Weinbroum AA.
Subanaesthetic ketamine spares postoperative morphine and controls pain better than
standard morphine does alone in orthopaedic-oncological patients. Eur J Cancer 2008;
44(7): 954-962.
160
Kömürcü S, Turhal S, Altundağ K, Atahan L, Turna HS, Manavoğlu O, Yavuz AA, Ozkök S,
Aliustaoğlu M, Altinbaş M, Pak Y, Cooper R, Yaylaci M, Demirkan B, Sarihan S, Ozdemir F.
Safety and efficacy of transdermal fentanyl in patients with cancer pain: Phase IV, Turkish
oncology group trial. Eur J Cancer Care (Engl.) 2007; 16(1): 67-73.
161
Kotb HI, Fouad IA, Fares KM, Mostafa MG, Abd El-Rahman AM. Pharmacokinetics of oral
tramadol in patients with liver cancer. J Opioid Manag 2008; 4(2): 99-104.
162
Krajnik M, Podolec Z, Siekierka M, Sykutera M, Pufal E, Sobanski P, Makarewicz R, Neef C,
Punt N, Zylicz ZMorphine inhalation by cancer patients: a comparison of different nebuli-
zation techniques using pharmacokinetic, spirometric, and gasometric parameters. J Pain
Symptom Manage 2009; 38(5): 747-757.
163
Kress HG, Oronska A, Kaczmarek Z, Kaasa S, Colberg T, Nolte T. Efficacy and tolerability of
intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer:
a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial
with a 10-month, open-label extension treatment period. Clin Ther 2009; 31(6): 1177-
1191.
164
Kress HG, Von der Laage D, Hoerauf KH, Nolte T, Heiskanen T, Petersen R, Lundorff L,
Sabatowski R, Krenn H, Rosland JH, Saedder EA, Jensen NH. A randomized, open, parallel
group, multicenter trial to investigate analgesic efficacy and safety of a new transdermal
fentanyl patch compared to standard opioid treatment in cancer pain. J Pain Symptom
Manage 2008; 36(3): 268-279.
165
Kretzschmar A, Wiegel T, Al-Batran S-E, Hinrichs HF, Kindler M, Steck T,
Literaturverzeichnis